Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL Positive B-Cell Acute Lymphoblastic Leukemia

NCT07301424 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT07301424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07301424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL Positive B-Cell Acute Lymphoblastic Leukemia
Lead sponsor
University of Alberta
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 2, 2027
Completion date
December 31, 2031
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all) philadelphia chromosome-positive (ph+), bcr-abl positive acute lymphoblastic leukemia